Chitinase-like protein YKL-40 correlates with inflammatory phenotypes, anti-asthma responsiveness and future exacerbations

Chitinase-like protein YKL-40 correlates with inflammatory phenotypes, anti-asthma responsiveness and future exacerbations.

Full text not available from this repository.
Item Type: Article
Status: Published
Official URL: https://doi.org/10.1186/s12931-019-1051-9
Journal or Publication Title: Respiratory Research
Volume: 20
Number: 1
Date: 2019
Divisions: UTS Centre for Inflammation
Depositing User: General Admin
Identification Number: 10.1186/s12931-019-1051-9
ISSN: 1465-993X
Date Deposited: 21 Dec 2020 22:50
Abstract:

Background: Asthma is a heterogeneous chronic airway disease, which may be classified into different phenotypes. YKL-40 is a chitin-binding glycoprotein with unclear functions, but its expression is associated with inflammation and tissue remodeling. However, few studies have explored whether YKL-40 is associated with inflammatory phenotypes of asthma.

Methods: The study had two parts. Study I (n = 115) was a one-year prospective cohort designed to explore the relationship of serum YKL-40 levels with inflammatory phenotypes of asthma at baseline, and during exacerbations. Study II (n = 62) was a four-week prospective cohort designed to define whether serum YKL-40 levels could predict responses to a fixed anti-asthma regimen. YKL-40, IL-6 and CCL22 levels were detected using ELISA, and a sputum inflammatory panel (including IL-1β, IL-5, IL-8 and TNF-α) was assessed using Luminex-based MILLIPLEX assay.

Results: Study I: Serum YKL-40 levels in non-eosinophilic asthma (NEA) i.e. neutrophilic (47.77 [29.59, 74.97] ng/mL, n = 40) and paucigranulocytic (47.36 [28.81, 61.68] ng/mL, n = 31) were significantly elevated compared with eosinophilic asthma (31.05 [22.41, 51.10] ng/mL, n = 44) (P = 0.015). Serum YKL-40levels positively correlated with blood neutrophils, sputum IL-1β and plasma IL-6 but negatively correlated with serum IgE and blood eosinophils (all P ≤ 0.05). Baseline YKL-40 levels predicted moderate to severe exacerbations within a one-year period (aOR = 4.13, 95% CI = [1.08, 15.83]). Study II: Serum YKL-40 was an independent biomarker of negative responses to anti-asthma regimens (adjusted Odds Ratio [aOR] = 0.82, 95% CI = [0.71, 0.96].

Conclusions: These studies show that YKL-40 is a non-type 2 inflammatory signature for NEA, which could predict responsiveness or insensitivity to anti-asthma medications and more exacerbations. Further studies are needed to assess whether monitoring YKL-40 levels could provide potential implications for clinical relevance.

Keywords: Asthma treatment response; Exacerbations; Inflammatory phenotypes; YKL-40.

Creators:
Creators
Email
Liu, Lei
UNSPECIFIED
Zhang, Xin
UNSPECIFIED
Liu, Ying
UNSPECIFIED
Zhang, Li
UNSPECIFIED
Zheng, Jing
UNSPECIFIED
Wang, Ji
UNSPECIFIED
Hansbro, Philip M.
UNSPECIFIED
Wang, Lei
UNSPECIFIED
Wang, Gang
UNSPECIFIED
Hsu, Alan Chen-Yu
UNSPECIFIED
Last Modified: 21 Dec 2020 22:50
URI: https://eprints.centenary.org.au/id/eprint/216

Actions (login required)

View Item View Item